Pyrazolopyrimidinone PDE2 Inhibitors With Selective CNS Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective PDE2 inhibitors with desirable pharmaceutical properties such as potency, selectivity, and a favorable side effect profile.
Innovation Solution
Development of pyrazolopyrimidinone compounds that act as potent and selective PDE2 inhibitors, useful in treating neurological and peripheral disorders, enhancing neuronal plasticity, and facilitating neurorecovery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing PDE inhibitors are used, then PDE2 inhibition activity is achieved, but selectivity and side effect profile are insufficient
Solution Approach 1:
The patent applies local quality by designing the pyrazolopyrimidinone core structure with specific substituent patterns that target PDE2's unique active site architecture. The compounds feature differentiated regions: a pyrazolopyrimidinone core for PDE2 binding, aromatic substituents for hydrophobic interactions, and specific functional groups for hydrogen bonding, creating localized interactions that achieve high selectivity for PDE2 over other PDE isoforms, thereby reducing off-target side effects
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the pyrazolopyrimidinone scaffold, including substituent types (aromatic, aliphatic, heterocyclic), substituent positions, and molecular weight ranges. These parameter optimizations tune the compounds' affinity for PDE2 while maintaining selectivity, achieving potent inhibition (IC50 values in nanomolar range) with favorable side effect profiles
2Productivity
If potent PDE2 inhibition is achieved, then cognitive and motor function improvement is enhanced, but pharmaceutical properties such as selectivity must be maintained
Solution Approach 1:
The patent applies dynamics by creating a series of pyrazolopyrimidinone compounds with varying degrees of PDE2 inhibition potency and selectivity. The dynamic optimization involves adjusting substituent parameters to achieve the right balance: compounds with aromatic substituents at specific positions provide optimal PDE2 binding affinity for cognitive enhancement, while maintaining structural features that differentiate them from other PDE isoforms, ensuring selective action
Solution Approach 2:
The patent incorporates feedback mechanisms through in vitro and in vivo testing of pyrazolopyrimidinone compounds to evaluate both PDE2 inhibition potency and selectivity. Data from enzyme assays, cellular models, and animal studies (including cognitive and motor function tests) feed back into the structure-activity relationship analysis, guiding further optimization of compound structures to enhance therapeutic effect while maintaining selectivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The pyrazolopyrimidinone compounds effectively inhibit PDE2, improving cognitive and motor functions, treating neurodegenerative disorders, and enhancing cognitive and motor training efficiency.
Implementation Method 1
PDE enzymes hydrolyze cAMP and cGMP by breaking phosphodiester bonds to form the corresponding monophosphates
Implementation Method 2
PDE enzymes hydrolyze cAMP and cGMP by breaking phosphodiester bonds to form the corresponding monophosphates
Data Source
AI summary
A chemical entity of Formula (I), wherein V, W, Y, and Z, have any of the values described herein, and compositions comprising such chemical entities, methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques, radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, cognitive disorders, neurodegenerative diseases, and trauma-dependent losses of function, enhancing the efficiency of cognitive and motor training, including in stroke or TBI rehabilitation; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, dermatoiogical, inflammatory, and pain disorders.